FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311432899> ?p ?o ?g. }

• W4311432899 endingPage "e2246604" @default.
• W4311432899 startingPage "e2246604" @default.
• W4311432899 abstract "Importance Direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection is associated with lower mortality and is effective in individuals with alcohol use disorder (AUD). However, despite recommendations, patients with AUD may be less likely to receive DAAs. Objective To assess the association between alcohol use and receipt of DAA treatment among patients with HCV within the Veterans Health Administration (VHA). Design, Setting, and Participants This cohort study included 133 753 patients with HCV born from 1945 to 1965 who had completed the Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) questionnaire and had at least 1 outpatient visit in the VHA from January 1, 2014, through May 31, 2017, with maximal follow-up of 3 years until May 31, 2020; DAA receipt; or death, whichever occurred first. Exposures Alcohol use categories generated using responses to the AUDIT-C questionnaire and International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses: current AUD, abstinent with AUD history, at-risk drinking, lower-risk drinking, and abstinent without AUD history. Demographic, other clinical, and pharmacy data were also collected. Main Outcomes and Measures Associations between alcohol use categories and DAA receipt within 1 and 3 years estimated using Cox proportional hazards regression stratified by calendar year. Results Of 133 753 patients (130 103 men [97%]; mean [SD] age, 60.6 [4.5] years; and 73 493 White patients [55%]), 38% had current AUD, 12% were abstinent with a history of AUD, 6% reported at-risk drinking, 14% reported lower-risk drinking, and 30% were abstinent without a history of AUD. Receipt of DAA treatment within 1 year was 7%, 33%, 53%, and 56% for patients entering the cohort in 2014, 2015, 2016, and 2017, respectively. For patients entering in 2014, those with current AUD (hazard ratio [HR], 0.72 [95%, CI, 0.66-0.77]) or who were abstinent with an AUD history (HR, 0.91 [95% CI, 0.84-1.00]) were less likely to receive DAA treatment within 1 year compared with patients with lower-risk drinking. For those entering in 2015-2017, patients with current AUD (HR, 0.75 [95% CI, 0.70-0.81]) and those who were abstinent with an AUD history (HR, 0.76 [95% CI, 0.68-0.86]) were less likely to receive DAA treatment within 1 year compared with patients with lower-risk drinking. Conclusions and Relevance This cohort study suggests that individuals with AUD, regardless of abstinence, were less likely to receive DAA treatment. Improved access to DAA treatment for persons with AUD is needed." @default.
• W4311432899 created "2022-12-26" @default.
• W4311432899 creator A5008472753 @default.
• W4311432899 creator A5019520040 @default.
• W4311432899 creator A5022598366 @default.
• W4311432899 creator A5025308612 @default.
• W4311432899 creator A5025733523 @default.
• W4311432899 creator A5031725279 @default.
• W4311432899 creator A5036614428 @default.
• W4311432899 creator A5042016074 @default.
• W4311432899 creator A5046216738 @default.
• W4311432899 creator A5051875554 @default.
• W4311432899 creator A5054343694 @default.
• W4311432899 creator A5062381819 @default.
• W4311432899 creator A5062404491 @default.
• W4311432899 creator A5063688150 @default.
• W4311432899 creator A5068543626 @default.
• W4311432899 creator A5075365513 @default.
• W4311432899 creator A5076431340 @default.
• W4311432899 creator A5089959397 @default.
• W4311432899 date "2022-12-14" @default.
• W4311432899 modified "2023-10-17" @default.
• W4311432899 title "Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment" @default.
• W4311432899 cites W1730038705 @default.
• W4311432899 cites W1826923552 @default.
• W4311432899 cites W1858796636 @default.
• W4311432899 cites W1909356815 @default.
• W4311432899 cites W1973979122 @default.
• W4311432899 cites W1974150037 @default.
• W4311432899 cites W1986115000 @default.
• W4311432899 cites W2004006565 @default.
• W4311432899 cites W2021751802 @default.
• W4311432899 cites W2022677793 @default.
• W4311432899 cites W2029162852 @default.
• W4311432899 cites W2033084007 @default.
• W4311432899 cites W2038935403 @default.
• W4311432899 cites W2053178989 @default.
• W4311432899 cites W2054488397 @default.
• W4311432899 cites W2056860390 @default.
• W4311432899 cites W2061784149 @default.
• W4311432899 cites W2064387090 @default.
• W4311432899 cites W2079047890 @default.
• W4311432899 cites W2081689022 @default.
• W4311432899 cites W2087331149 @default.
• W4311432899 cites W2092433392 @default.
• W4311432899 cites W2098658501 @default.
• W4311432899 cites W2107026089 @default.
• W4311432899 cites W2130135269 @default.
• W4311432899 cites W2162943353 @default.
• W4311432899 cites W2163727088 @default.
• W4311432899 cites W2164842638 @default.
• W4311432899 cites W2275737843 @default.
• W4311432899 cites W2285708562 @default.
• W4311432899 cites W2320055119 @default.
• W4311432899 cites W2328909886 @default.
• W4311432899 cites W2344462850 @default.
• W4311432899 cites W2356495879 @default.
• W4311432899 cites W2521423916 @default.
• W4311432899 cites W2533471076 @default.
• W4311432899 cites W2615509354 @default.
• W4311432899 cites W2626787196 @default.
• W4311432899 cites W2758322164 @default.
• W4311432899 cites W2763232889 @default.
• W4311432899 cites W2765241413 @default.
• W4311432899 cites W2792592120 @default.
• W4311432899 cites W2810799634 @default.
• W4311432899 cites W2890038704 @default.
• W4311432899 cites W2916207656 @default.
• W4311432899 cites W2940827946 @default.
• W4311432899 cites W2945101057 @default.
• W4311432899 cites W2947568558 @default.
• W4311432899 cites W2969919847 @default.
• W4311432899 cites W2982119113 @default.
• W4311432899 cites W2998556261 @default.
• W4311432899 cites W3011008216 @default.
• W4311432899 cites W3044995086 @default.
• W4311432899 cites W3077337725 @default.
• W4311432899 cites W3122703795 @default.
• W4311432899 cites W3155369121 @default.
• W4311432899 cites W3196260705 @default.
• W4311432899 cites W4212959796 @default.
• W4311432899 cites W4230981052 @default.
• W4311432899 cites W4233817495 @default.
• W4311432899 cites W4237805430 @default.
• W4311432899 cites W4239728154 @default.
• W4311432899 cites W4240729260 @default.
• W4311432899 cites W4240925651 @default.
• W4311432899 cites W4245346619 @default.
• W4311432899 cites W4245997369 @default.
• W4311432899 cites W4246105734 @default.
• W4311432899 cites W4248668511 @default.
• W4311432899 cites W4252438698 @default.
• W4311432899 cites W4253209400 @default.
• W4311432899 cites W4254503909 @default.
• W4311432899 cites W4254933197 @default.
• W4311432899 doi "https://doi.org/10.1001/jamanetworkopen.2022.46604" @default.
• W4311432899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36515952" @default.
• W4311432899 hasPublicationYear "2022" @default.

• next